Updates are available Correction dated 2023-07-28
Click to view Correction: https://doi.org/10.1245/s10434-023-14026-w
-
Authors
Kobayashi, Shin http://orcid.org/0000-0001-9321-8452
Ikeda, Masafumi
Nakachi, Kohei
Ueno, Makoto
Okusaka, Takuji
Todaka, Akiko
Satoi, Sohei
Tomokuni, Akira
Konishi, Masaru
Furuse, Junji
-
Funding
Funding for this research was provided by:
Ministry of Health, Labour and Welfare (H26-076)
Japan Agency for Medical Research and Development (16ck0106079h0003, 17ck0106350h0001)
National Cancer Center Japan (23-A-22, 26-A-4, 29-A-3)
- License Information
-
More Information
Article History
Received: 4 April 2023
Accepted: 12 June 2023
First Online: 14 July 2023
Change Date: 28 July 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1245/s10434-023-14026-w
Disclosure
: Masafumi Ikeda; honoraria, AstraZeneca, AbbVie, Abbott Japan, Bayer, Bristol-Myers Squibb, Chiome Bioscience, Chugai, EA Pharma, Eisai, Eli Lilly Japan, Fujifilm Toyama Chemical, Delta-Fly Pharma, Incyte Biosciences Japan, Invitae, J-Pharma, Merus N.V., Merck biopharma, MSD, Nippon Kayaku, Novartis, NIHON SERVIER, Otsuka, Ono, Pfizer, Syneos Health, Takeda, Taiho, Taisho Pharmaceutical, Teijin, Yakult Makoto Ueno; honoraria and research funding, Taiho Pharmaceutical, AstraZeneca, Yakult Honsha, MSD, Nihon Servier, Ono Pharmaceutical, Incyte, CHUGAI PHARMACEUTICAL, Boehringer Ingelheim, J-pharma, Daiichi Sankyo, Eisai, Takeda Pharmaceutical, Merck Biopharma, Astellas Pharma, DFP, Novartis Takuji Okusaka; honoraria, consulting and advisory role, and research funding, Taiho Pharmaceutical, AstraZeneca, Syneos Health, EP clude, Eisai, MSD, Insight Japan, Nihon Servier, Dainippon Sumitomo Pharma, Bristol-Myers, FUJIFILM Toyama Chemical, Ono Pharmaceutical, Yakult Honsha, Johnson & Johnson, Daiichi Sankyo, Chugai Pharmaceutical, Nippon Shinyaku, Eli Lilly Japan, Pfizer Japan, Novartis Pharma. Akiko Todaka; honoraria, Ono Pharmaceutical, Yakult Honsha, Taiho Pharmaceutical, and Nihon Servier. Sohei Satoi; research funding, Nihon Servier. Junji Furuse; honoraria and research funding, Ono Pharmaceutical, Chugai Pharma, Incyte Biosciences Japan, Eisai, Eli Lilly Japan, Astra Zeneca, Yakult Honsha, Servier Japan, MSD, Novartis Pharma, Takeda, Bayer, Taiho Pharmaceutical, EA Pharma, Teijin pharma, Daiichi Sankyo, Terumo, Astellas, Sanofy, J-Pharma, Sumitomo Dainippon, Taiho Pharmaceutical, Delta-Fly-Pharma. Shin Kobayashi; none to declare. Kohei Nakachi; none to declare. Akira Tomokuni; none to declare. Masaru Konishi; none to declare
